News

21
Dec 2022

BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis

BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
01
Dec 2022

BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference

BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
04
Nov 2022

BenevolentAI to present at Jefferies Investor Conference in November

BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
06
Oct 2022

BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca

Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.